Table 1.
Baseline demographic and clinical characteristics
| Placebo (n=66) | Dalcetrapib (n=64) | |
|---|---|---|
| Age, years | 64·6 (7·8) | 62·6 (8·2) |
|
| ||
| Male sex | 55 (83%) | 51 (80%) |
|
| ||
| Body-mass index (kg/m2) | 29·8 (6·2) | 29·6 (4·8) |
|
| ||
| White race* | 62 (94%) | 58 (91%) |
|
| ||
| Medical history of | ||
| Coronary heart disease | 54 (82%) | 57 (89%) |
| Symptomatic coronary artery disease | 5 (8%) | 5 (8%) |
| Hypertension | 48 (73%) | 47 (73%) |
| Type 2 diabetes | 20 (30%) | 19 (30%) |
| Abdominal aortic aneurysm | 2 (3%) | 3 (5%) |
| Peripheral arterial disease | 10 (15%) | 6 (9%) |
|
| ||
| Present smoker | 8 (12%) | 9 (14%) |
|
| ||
| High sensitivity C-reactive protein, mg/L(median, IQR) | 1·4 (0·8–2·8) | 1·4 (0·6–3·7) |
|
| ||
| Statin use | 61 (92%) | 52 (81%) |
|
| ||
| Apolipoprotein B (g/L) | 0·8 (0·2) | 0·8 (0·2) |
|
| ||
| Apolipoprotein A1 (g/L) | 1·4 (0·3) | 1·4 (0·2) |
|
| ||
| Plasma lipid profile | ||
| Total cholesterol, mmol/L | 3·8 (0·7) | 3·7 (0·7) |
| HDL-C, mmol/L | 1·2 (0·4) | 1·1 (0·3) |
| LDL-C, mmol/L | 1·9 (0·5) | 1·9 (0·6) |
| Triglycerides, mmol/L (median, IQR) | 1·5 (1·0–1·8) | 1·4 (1·0–1·9) |
|
| ||
| MRI (average carotid)† | ||
| Total vessel area, mm2 | 60·2 (12·9) | 62·8 (17·8) |
| Wall area, mm2 | 29·5 (8·9) | 30·0 (9·3) |
| Wall thickness, mm | 1·23 (0·29) | 1·21 (0·22) |
| Normalised wall index, % | 48·1 (6·91) | 47·1 (5·93) |
|
| ||
| PET/CT index vessel‡ | ||
| Aorta | 47 (84%) | 50 (88%) |
| Left carotid | 6 (11%) | 0 |
| Right carotid | 3 (5%) | 7 (12%) |
|
| ||
| PET/CT target-to-background ratio§ | ||
| Most diseased segment mean of maximum | 2·8 (0·7) | 2·7 (0·7) |
| Mean of maximum | 2·6 (0·6) | 2·5 (0·6) |
| Mean of mean | 1·9 (0·3) | 1·8 (0·4) |
Data are n (%) or mean (SD) unless otherwise stated. IQR=interquartle range. HDL-C=high-density lipoprotein-cholesterol. LDL-C=low-density lipoprotein-cholesterol.
*
Race or ethnic group was determined by the investigators.
†
Total number of patients with MRI vessel parameter measurements was 56 for placebo and 58 for dalcetrapib. Includes all patients with measurements available.
‡
Total number of patients with PET/CT data was 56 for placebo and 57 for dalcetrapib.
§
Total number of patients with target-to-background ratio measurements was 56 for placebo and 56 for dalcetrapib.